NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population

Last updated: November 13, 2025
Sponsor: NVT GmbH
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03613246
NVT04FOL
  • Ages > 18
  • All Genders

Study Summary

The study collects real-world data of patients who were treated with the ALLEGRA TAVI System TF and evaluates early and midterm clinical and quality of life outcome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Symptomatic degeneration of severe calcified aortic heart valve OR failing surgicalaortic bioprosthetic valve

  2. Acceptable candidate for elective treatment with the ALLEGRA TAVI System TF (according to the most recent version of the ALLEGRA Instructions For Use)

  3. High risk for surgery as assessed by the heart team

  4. Has signed the Patient Informed Consent Form >= 18 years

Exclusion

Exclusion Criteria:

General:

  1. Echocardiographic evidence of intracardiac thrombus or vegetation

  2. Significant aortic disease such as severe obstructive calcification or markedtortuosity or kinking which will preclude a safe advancement of the ALLEGRA TAVISystem TF

  3. Iliofemoral vessel conditions such as severe obstructive calcification, severetortuosity or kinking that would preclude safe placement of an 18 Fr introducersheath or make endovascular access to the aortic valve impossible

  4. Severe ventricular dysfunction with LVEF <20%

  5. Evidence of active endocarditis or other acute infections

  6. Renal failure requiring continuous renal replacement therapy

  7. Known hypersensitivity to contrast media, which cannot be adequately pre-medicatedor contraindication to anticoagulant or anti-platelet medication or to nitinol alloyor to bovine tissue

  8. Life expectancy ≤ 12 months due to other medical illness

  9. Currently participating in another investigational drug or device study

Patients with native aortic valve disease:

  1. Unicuspid or bicuspid aortic valve

  2. Non-calcified aortic stenosis

  3. Combined aortic valve disease with predominant aortic regurgitation > 3

  4. Distance between aortic valve basal plane and the orifice of the lowest coronaryartery < 8 mm

Patients with degenerated surgical bioprosthetic aortic valves:

  1. Low position of the coronary ostia, especially in combination with shallow sinuses

  2. Internal diameter of the bioprosthesis is ≤16 mm or >28 mm

  3. Partially detached leaflets that in the aortic position may obstruct a coronaryostium

Study Design

Total Participants: 346
Study Start date:
February 20, 2019
Estimated Completion Date:
January 26, 2029

Connect with a study center

  • Oulu University Hospital

    Oulu, 90220
    Finland

    Site Not Available

  • Oulu University Hospital

    Oulu 643492, 90220
    Finland

    Site Not Available

  • Herz- und Gefäßzentrum Bad Bevensen

    Bad Bevensen, 29549
    Germany

    Site Not Available

  • Herz- und Gefäßzentrum Bad Bevensen

    Bad Bevensen 2949511, 29549
    Germany

    Site Not Available

  • Schuechtermann-klinik

    Bad Rothenfelde,
    Germany

    Site Not Available

  • Schuechtermann-klinik

    Bad Rothenfelde 2953367,
    Germany

    Site Not Available

  • Kath. Marienkrankenhaus

    Hamburg, 22087
    Germany

    Site Not Available

  • Kath. Marienkrankenhaus

    Hamburg 2911298, 22087
    Germany

    Site Not Available

  • MH Hannover

    Hannover, 30625
    Germany

    Site Not Available

  • MH Hannover

    Hanover 2910831, 30625
    Germany

    Site Not Available

  • SLK-Kliniken Heilbronn

    Heilbronn, 74078
    Germany

    Site Not Available

  • SLK-Kliniken Heilbronn

    Heilbronn 2907669, 74078
    Germany

    Site Not Available

  • Ospedale San Raffaele

    Milan, 20132
    Italy

    Site Not Available

  • Ospedale San Raffaele

    Milan 3173435, 20132
    Italy

    Site Not Available

  • Clinica Mediterranea Neapel

    Naples,
    Italy

    Site Not Available

  • Clinica Mediterranea Neapel

    Naples 3172394,
    Italy

    Site Not Available

  • Heartcentre Catharina Hospital Eindhoven

    Eindhoven, 5623 EJ
    Netherlands

    Site Not Available

  • Heartcentre Catharina Hospital Eindhoven

    Eindhoven 2756253, 5623 EJ
    Netherlands

    Site Not Available

  • Hospital Universitario La Paz

    Madrid, 28046
    Spain

    Site Not Available

  • Hospital Universitario La Paz

    Madrid 3117735, 28046
    Spain

    Site Not Available

  • Hospital Universitario Virgen de la Victoria

    Málaga, 29010
    Spain

    Site Not Available

  • Hospital Universitario Virgen de la Victoria

    Málaga 2514256, 29010
    Spain

    Site Not Available

  • Hospital Universitario de Salamanca

    Salamanca, 37007
    Spain

    Site Not Available

  • Hospital Universitario de Salamanca

    Salamanca 3111108, 37007
    Spain

    Site Not Available

  • Hospital Alvaro Cunqueiro

    Vigo, 36213
    Spain

    Site Not Available

  • Hospital Alvaro Cunqueiro

    Vigo 3105976, 36213
    Spain

    Site Not Available

  • Morriston Hospital

    Swansea,
    United Kingdom

    Site Not Available

  • Morriston Hospital

    Swansea 2636432,
    United Kingdom

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.